![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-announces-the-closing-of-up-to-70-million-concurrent-private-placement-and-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-302182326.html
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-announces-up-to-70-million-concurrent-private-placement-and-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-302180012.html
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update-302141088.html
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-doses-first-patient-in-its-phase-1-clinical-trial-evaluating-da-1726-for-the-treatment-of-obesity-302118491.html
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-reports-year-end-2023-financial-results-and-provides-corporate-update-302101543.html
https://www.neurobopharma.com/news-releases/news-release-details/neurobo-pharmaceuticals-participate-bio-ceo-investor-conference
https://www.neurobopharma.com/news-releases/news-release-details/neurobo-pharmaceuticals-announces-fda-clearance-ind-phase-1
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-reports-positive-pre-clinical-safety-data-of-da-1241-in-combination-with-sitagliptin-and-opens-enrollment-for-part-2-of-its-phase-2a-clinical-trial-evaluating-da-1241-for-the-treatment-of-mash-302037445.html
https://www.prnewswire.com/news-releases/neurobo-pharmaceuticals-regains-compliance-with-nasdaq-minimum-price-requirement-302028819.html
https://www.neurobopharma.com/news-releases/news-release-details/neurobo-participate-industry-and-investor-conferences-january